An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.

David J KuterHasan A AlbitarScott E OlitskyMarianne S ClancyVivek N Iyer

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)

Systemic bevacizumab is widely used to treat bleeding in HHT with excellent physician-reported effectiveness and safety. There is considerable variation in maintenance treatment practices and thresholds for initiation of bevacizumab among HHT centres.

Keyphrases

metastatic colorectal cancer
primary care
atrial fibrillation
emergency department
healthcare
cross sectional
drug induced